TRIAL DETAIL
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
2 |
Start Date 03/01/2012 |
Age of Trial (yrs) 12.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + MEK inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CMEK162X2109, EUDRACT: 2011-002578-21 |
|||
Sponsor: |
Array BioPharma |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
100 Blossom St |
Charlestown |
MA |
02114 |
USA |
|
2000 Circle of Hope |
Salt Lake City |
UT |
84103 |
USA |
|
Grattan Street |
Parkville |
Victoria |
3050 |
Australia |
|
Villejuif |
Val de Narne |
94805 |
France |
||
119-129 |
Barcelona |
08035 |
Spain |
||
Surrey |
sM2 5PT |
UK |
|||
La Jolla |
CA |
92093 |
USA |
||
675 North St. Clair |
Chicago |
IL |
60611 |
USA |
|
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
Bellinzona |
Switzerland |